scispace - formally typeset
J

Jan L. Breslow

Researcher at Rockefeller University

Publications -  250
Citations -  29865

Jan L. Breslow is an academic researcher from Rockefeller University. The author has contributed to research in topics: Cholesterol & Apolipoprotein B. The author has an hindex of 95, co-authored 249 publications receiving 28925 citations.

Papers
More filters
Journal ArticleDOI

Low-Density Lipoprotein Subclass Patterns and Risk of Myocardial Infarction

TL;DR: The association of low-density lipoprotein (LDL) subclass patterns with coronary heart disease was investigated in a case-control study of nonfatal myocardial infarction and multivariate logistic regression analyses showed that both high-density cholesterol and triglyceride levels contributed to the risk associated with the small, dense LDL subclass pattern.
Journal ArticleDOI

Moderate Alcohol Intake, Increased Levels of High-Density Lipoprotein and Its Subfractions, and Decreased Risk of Myocardial Infarction

TL;DR: The inverse association of moderate alcohol intake with the risk of myocardial infarction is confirmed and support the view that the effect is mediated, in large part, by increases in both HDL2 and HDL3.
Journal ArticleDOI

Upregulation of VCAM-1 and ICAM-1 at Atherosclerosis-Prone Sites on the Endothelium in the ApoE-Deficient Mouse

TL;DR: The levels, localization, and characteristics of expression of VCAM-1, ICAM-2, and PECam-1 appear to be differentially regulated, and upregulation of VC AM-1 and ICAM -1 is associated with sites of lesion formation.
Journal ArticleDOI

Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance

TL;DR: A direct and causative relationship between the accumulation of intracellular fatty acid-derived metabolites and insulin resistance mediated via alterations in the insulin signaling pathway is suggested, independent of circulating adipocyte-derived hormones.
Journal ArticleDOI

n−3 Fatty acids and cardiovascular disease

TL;DR: Directions for future research include RCTs to confirm the initial trials showing that EPA plus DHA decreases cardiovascular death and additional studies to determine whether this effect is due to EPA, DHA, or the combination; the dosage of the effective components; and whether the mechanism of action in humans is prevention of fatal arrhythmias.